Physician profile
Roza Cieszkowski
NPI 1316911506
$2,190.75
in general payments reported to CMS, 2019-2025
11 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $54.98 · 2021: $18.08 · 2022: $299 · 2023: $817 · 2024: $150 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.57 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $368.04 | 2022-2025 | Caplyta |
| Alkermes, INC. | $353.16 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Axsome Therapeutics, INC. | $253.18 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $210.02 | 2019-2025 | Rexulti |
| Allergan, INC. | $189.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Spravato |
| Lundbeck LLC | $92.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.63 | 2020 | |
| Abbott Laboratories | $23.43 | 2023 | Freestyle Libre 2 |
| Corium, LLC | $6.15 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roza Cieszkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.